These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22820249)

  • 1. Profound conformational changes of PED/PEA-15 in ERK2 complex revealed by NMR backbone dynamics.
    Twomey EC; Cordasco DF; Wei Y
    Biochim Biophys Acta; 2012 Dec; 1824(12):1382-93. PubMed ID: 22820249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMR backbone dynamics studies of human PED/PEA-15 outline protein functional sites.
    Farina B; Pirone L; Russo L; Viparelli F; Doti N; Pedone C; Pedone EM; Fattorusso R
    FEBS J; 2010 Oct; 277(20):4229-40. PubMed ID: 20825483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEA-15 C-Terminal Tail Allosterically Modulates Death-Effector Domain Conformation and Facilitates Protein-Protein Interactions.
    Crespo-Flores SL; Cabezas A; Hassan S; Wei Y
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK.
    Mace PD; Wallez Y; Egger MF; Dobaczewska MK; Robinson H; Pasquale EB; Riedl SJ
    Nat Commun; 2013; 4():1681. PubMed ID: 23575685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions.
    Whitehurst AW; Robinson FL; Moore MS; Cobb MH
    J Biol Chem; 2004 Mar; 279(13):12840-7. PubMed ID: 14707138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site.
    Callaway K; Abramczyk O; Martin L; Dalby KN
    Biochemistry; 2007 Aug; 46(32):9187-98. PubMed ID: 17658892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Studies of ERK2 Protein Complexes.
    Weijman JF; Riedl SJ; Mace PD
    Methods Mol Biol; 2017; 1487():53-63. PubMed ID: 27924558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of the PED/PEA15 interaction with the C-terminal fragment of phospholipase D1 revealed by NMR spectroscopy.
    Farina B; Doti N; Pirone L; Malgieri G; Pedone EM; Ruvo M; Fattorusso R
    Biochim Biophys Acta; 2013 Aug; 1834(8):1572-80. PubMed ID: 23608947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-definition NMR structure of PED/PEA-15 death effector domain reveals details of key polar side chain interactions.
    Twomey EC; Wei Y
    Biochem Biophys Res Commun; 2012 Jul; 424(1):141-6. PubMed ID: 22732408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEA-15 engages in allosteric interactions using a common scaffold in a phosphorylation-dependent manner.
    Ikedife J; He J; Wei Y
    Sci Rep; 2022 Jan; 12(1):116. PubMed ID: 34997083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2.
    Eblen ST; Catling AD; Assanah MC; Weber MJ
    Mol Cell Biol; 2001 Jan; 21(1):249-59. PubMed ID: 11113199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering and cytosolic delivery of a native regulatory protein and its variants for modulation of ERK2 signaling pathway.
    Ryou JH; Sohn YK; Kim DG; Kyeong HH; Kim HS
    Biotechnol Bioeng; 2018 Apr; 115(4):839-849. PubMed ID: 29240226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain.
    Hill JM; Vaidyanathan H; Ramos JW; Ginsberg MH; Werner MH
    EMBO J; 2002 Dec; 21(23):6494-504. PubMed ID: 12456656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis.
    Condorelli G; Vigliotta G; Cafieri A; Trencia A; Andalò P; Oriente F; Miele C; Caruso M; Formisano P; Beguinot F
    Oncogene; 1999 Aug; 18(31):4409-15. PubMed ID: 10442631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docking interactions induce exposure of activation loop in the MAP kinase ERK2.
    Zhou T; Sun L; Humphreys J; Goldsmith EJ
    Structure; 2006 Jun; 14(6):1011-9. PubMed ID: 16765894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targetting PED/PEA-15 for diabetes treatment.
    Fiory F; Spinelli R; Raciti GA; Parrillo L; D'esposito V; Formisano P; Miele C; Beguinot F
    Expert Opin Ther Targets; 2017 Jun; 21(6):571-581. PubMed ID: 28395542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying ERK2-protein interactions by fluorescence anisotropy: PEA-15 inhibits ERK2 by blocking the binding of DEJL domains.
    Callaway K; Rainey MA; Dalby KN
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):316-23. PubMed ID: 16324895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD.
    Renganathan H; Vaidyanathan H; Knapinska A; Ramos JW
    Biochem J; 2005 Sep; 390(Pt 3):729-35. PubMed ID: 15916534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solution NMR insights into docking interactions involving inactive ERK2.
    Piserchio A; Warthaka M; Devkota AK; Kaoud TS; Lee S; Abramczyk O; Ren P; Dalby KN; Ghose R
    Biochemistry; 2011 May; 50(18):3660-72. PubMed ID: 21449613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states.
    Greig FH; Nixon GF
    Pharmacol Ther; 2014 Sep; 143(3):265-74. PubMed ID: 24657708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.